Registration

PARDES BIOSCIENCES, INC. for PARDES BIOSCIENCES, INC.

Firm
Client
Income
—
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Funding for COVID-19 Therapeutics, specifically Oral Antivirals. Advance Purchase Agreements Strategic National Stockpile Pandemic Preparedness

LobbyistCovered position, as disclosed
JOHN MARTIN New Principal Associate Commissioner, FDA Legislative Director, Sen. Tom Cotton

Health Issues HCR

Funding for COVID-19 Therapeutics, specifically Oral Antivirals. Advance Purchase Agreements Strategic National Stockpile Pandemic Preparedness

LobbyistCovered position, as disclosed
JOHN MARTIN New Principal Associate Commissioner, FDA Legislative Director, Sen. Tom Cotton

Medical/Disease Research/Clinical Labs MED

Funding for COVID-19 Therapeutics, specifically Oral Antivirals. Advance Purchase Agreements Strategic National Stockpile Pandemic Preparedness

LobbyistCovered position, as disclosed
JOHN MARTIN New Principal Associate Commissioner, FDA Legislative Director, Sen. Tom Cotton

Medicare/Medicaid MMM

Funding for COVID-19 Therapeutics, specifically Oral Antivirals. Advance Purchase Agreements Strategic National Stockpile Pandemic Preparedness

LobbyistCovered position, as disclosed
JOHN MARTIN New Principal Associate Commissioner, FDA Legislative Director, Sen. Tom Cotton

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.